Jeff Bird has been a life science investor for nearly twenty years at Sutter Hill Ventures. In 2019, he formed Bluebird Ventures. He is on the board of two public companies, Portola Pharmaceuticals and Forty Seven, Inc. He served as CEO of Verinata, a developer of non-invasive prenatal diagnostics which was sold to Illumina. Prior to Sutter Hill Ventures, he was an executive at Gilead Sciences for 15 years, most recently as Senior Vice President of Business Operations which included global sales and marketing. Jeff received an MD and PhD (Cancer Biology) degree from Stanford Medical School, and was a Stanford undergraduate.